1361415-84-0 Usage
Uses
Given the provided materials, there are no explicit uses mentioned for (S)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol. However, based on its structural features, one could hypothesize potential applications in various fields such as pharmaceuticals, materials science, or chemical research. These applications would need to be confirmed through experimental data and scientific investigation.
Used in Pharmaceutical Industry:
(S)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol could potentially be used as a starting material or a building block for the development of new pharmaceutical compounds, given its complex structure and the presence of pharmacophore-like elements.
Used in Chemical Research:
As a novel compound, it might serve as a subject of interest in chemical research for understanding its reactivity, stability, and potential to form new derivatives with various applications.
Used in Materials Science:
(S)-(4-fluorophenyl)(4-((5-methyl-1H-pyrazol-3-yl)amino)quinazolin-2-yl)methanol's unique structure might offer properties that could be exploited in the development of new materials with specific characteristics for use in industries such as electronics, coatings, or advanced materials.
Check Digit Verification of cas no
The CAS Registry Mumber 1361415-84-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,1,4,1 and 5 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1361415-84:
(9*1)+(8*3)+(7*6)+(6*1)+(5*4)+(4*1)+(3*5)+(2*8)+(1*4)=140
140 % 10 = 0
So 1361415-84-0 is a valid CAS Registry Number.
1361415-84-0Relevant academic research and scientific papers
THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PI3K INHIBITOR, A JAK-2 INHIBITOR AND/OR A CDK 4/6 INHIBITOR
-
, (2016/02/29)
Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ, a Janus kinase-2 (JAK-2) inhibitor, a cyclin-dependent kinase- 4/6 (CDK4/6) inhibitor, and/or a Bruton's tyrosine kinase (BTK) inhibitor are described. In certain embodiments, the invention includes therapeutic combinations of a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor and a BTK inhibitor, a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a JAK-2, PI3K-δ, and BTK inhibitor.
SOLID FORMS COMPRISING OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, COMPOSITIONS THEREOF, AND USES THEREWITH
-
, (2013/09/12)
Solid forms comprising pyrazolylaminoquinazoline, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.
OPTICALLY ACTIVE PYRAZOLYLAMINOQUINAZOLINE, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
-
, (2012/03/12)
Provided herein is an optically active pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided herein is a method for treating, preventing, or ameliorating one or more symptoms of a JAK-mediated condition, disorder, or disease. F
